Visiongainโs latest report, Cell & Gene Therapy Market Report 2026-2036, provides detailed forecasts and strategic analysis across therapy type, indication, vector type, and end-user segments, including technology trends, trade and supply chain dynamics, and competitive positioning.
The global cell & gene therapy market is projected to grow from US$25.78 billion in 2026 to US$126.86 billion by 2036, at a CAGR of 17.3% during the forecast period. The market is expected to add over US$101 billion in value, driven by rising genetic disease prevalence, increasing regulatory approvals, and continued advances in gene editing and cell engineering technologies.
Key Market Insights
The global cell & gene therapy market will reach US$126.86 billion by 2036, growing at a CAGR of 17.3%
Growth is driven by increasing genetic disease burden, regulatory approvals, and technological innovation
Key regions: North America, Europe, Asia Pacific
Leading companies: Novartis AG, Gilead Sciences, Bristol-Myers Squibb, CRISPR Therapeutics
Key trend: Transition from experimental therapies to commercial-scale deployment
Download Free Sample Report (incl. forecasts, market data, and methodology)
Regulatory approvals are increasing across key markets, supporting the transition of cell & gene therapies into commercial use. Agencies such as the U.S. Food and Drug Administration are approving therapies across oncology and rare diseases, reflecting growing confidence in safety and efficacy. Expanded indications and broader patient eligibility are further accelerating adoption.
Progress in Manufacturing Technologies Supporting Scale-Up
Advances in manufacturing technologies are improving scalability and consistency. Automated, closed-system production platforms and improvements in viral vector production are reducing complexity and enabling more reliable output. These developments are critical as therapies move from clinical trials to wider commercial use.
Technology & Innovation
Gene Editing and Advanced Cell Engineering
Technologies such as CRISPR and next-generation CAR-T therapies are improving precision and enabling treatment of previously untreatable conditions. Integration of genomic data and personalised medicine approaches is expanding therapeutic applications and improving outcomes.
Trade & Supply Chain Dynamics
Global trade dynamics are shaping the cell & gene therapy market through supply chain dependencies on specialised materials such as viral vectors, reagents, and bioprocessing systems.
The market relies on globally distributed suppliers, creating exposure to tariffs, regulatory restrictions, and geopolitical uncertainty. Rather than sudden disruptions, cost pressures are emerging gradually through supplier concentration and import dependencies.
At the same time, regulatory scrutiny and policy changes related to biologics manufacturing and cross-border data transfer are increasing operational complexity and influencing sourcing strategies.
Commercial Impact
Cost pressure: Rising input and manufacturing costs are increasing overall therapy pricing
Supply chain shifts: Companies are investing in localised production and diversified sourcing
Margin implications: Smaller biotech firms face greater cost exposure than large pharmaceutical companies
Competitive positioning: Firms with integrated supply chains and strong manufacturing capabilities are advantaged
Market Opportunities
Expansion of Healthcare Infrastructure Enabling Adoption
Investment in specialised treatment centres, logistics, and cold-chain infrastructure is supporting wider adoption of advanced therapies. As healthcare systems expand capabilities for cell collection, processing, and administration, barriers to treatment access are gradually reducing.
Government Funding Supporting Innovation
Public investment in biotechnology research is accelerating development of next-generation therapies. Funding programmes supporting gene editing, rare disease research, and clinical infrastructure are strengthening the overall development ecosystem and expanding the therapy pipeline.
Competitive Landscape
The major players operating in the cell & gene therapy market include Adaptimmune, Allogene Therapeutics, Atara Biotherapeutics, Beam Therapeutics, BioMarin, Bristol-Myers Squibb Company, Catalent, CRISPR Therapeutics, GenScript, Gilead Sciences, Intellia Therapeutics, Johnson & Johnson, Lonza, MeiraGTx, Novartis AG, Sarepta Therapeutics, Ultragenyx Pharmaceutical, and Vertex Pharmaceuticals.
These companies are focusing on R&D, partnerships, manufacturing scale-up, and pipeline expansion to strengthen their market positions.
Recent Developments
April 2026 โ Beam Therapeutics: Published Phase 1/2 clinical data for BEAM-101 demonstrating promising results in sickle cell disease treatment
March 2026 โ U.S. Food and Drug Administration: Approved Kresladi, the first gene therapy for Leukocyte Adhesion Deficiency Type I
February 2026 โ Eli Lilly: Announced acquisition of Orna Therapeutics to expand RNA-based cell therapy capabilities
Frequently Asked Questions
What is driving growth in the cell & gene therapy market? Growth is driven by rising genetic disease prevalence, increasing approvals, and advances in gene editing technologies.
How are trade and supply chain dynamics affecting the market? Supply chain dependencies and regulatory complexity are increasing costs and influencing sourcing strategies.
Who are the leading companies in the market? Key players include Novartis, Gilead Sciences, Bristol-Myers Squibb, CRISPR Therapeutics, and Vertex Pharmaceuticals.
Download Free Sample Report (incl. forecasts, market data, and methodology)
Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.
